In this edition of Guided by Science, we define a few key terms that are frequently lost in translation to help you better understand how the immune system works and the promise of immuno-oncology.
While the $1 billion announced to fund this initiative is a large figure on its own, the effort will need to hyper-focus its resources and influence to make a meaningful impact. In this issue, we explore some practical ways that Cancer Moonshot 2020 can make good on its promise to improve outcomes for patients everywhere.
As the cancer treatment landscape shifts from traditional to immune-targeted therapies, it’s important to understand the benefits and limitations of each approach. By examining the faces of immunotherapy, we can best understand how immunotherapy is changing the world.
At the forefront of this revolution is the idea of combining therapies to combat the many ways cancers can adapt and survive. As our understanding of cancer and the immune system grows, we are witnessing the emergence of a new vision – where practical combinations can benefit many more patients now faced with life-threatening disease.
Last week, sunny San Diego was the site of a big event (no, I don’t mean, Comic Con): the 2014 DNA Vaccine Conference hosted by the International Society of DNA Vaccines (ISDV). I thought I’d take the opportunity to describe some of the “best of conference,” as seen through the completely biased eyes of OncoSec’s CMO and what it means for our mission of furthering intratumoral immunotherapy.
This past month, OncoSec’s Chief Medical Officer, Dr. Robert Pierce, participated in the 6th Annual Melanoma Research Alliance Scientific Retreat The conference seeks to advance the field of melanoma research, by providing an interactive forum that facilitates data sharing and discussion among key field leaders. This is accomplished through guest participation in a series of collaborative and thought-provoking activities, including panel discussions and notable speaker presentations.
SAN DIEGO – January 7, 2014 — OncoSec Medical Inc. (OTCQB: ONCS), a biotechnology company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will provide a corporate update at Biotech Showcase 2014; one of the world’s largest life sciences conferences held annually in San Francisco.
The presentation is scheduled to take place on Tuesday, January 14 at 2:30 p.m. PST at the Parc 55 Wyndham San Francisco–Union Square, located at 55 Cyril Magnin Street. A live webcast will be available by visiting the following link: http://www.media-server.com/m/p/byw47js4.
About Biotech Showcase 2014
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.
Now in its sixth year, Biotech Showcase is expected to attract upwards of 1,700 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry and time-relevant topics, as well as presentations from both private and public companies.
SAN DIEGO – January 11, 2014 — OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present at “TEN”; Noble Financial Capital Markets’ Tenth Annual Equity Conference, at Club Med in Sandpiper Bay, Florida, on Tuesday, January 21 at 1:30 p.m. (EST) in Room 1.
At the time of the presentation, a live audio and high-definition video webcast of OncoSec’s presentation will be available at the following link:
OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. Participants will require a Microsoft Silverlight viewer (a free download from the presentation link) in order to participate.
About Noble Financial Capital Markets
Noble Financial Capital Markets was established in 1984; 2014 marks its 30th Anniversary. Noble Financial is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in Boston, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 120 – 150 presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com